ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. It effectively shields cells from diverse toxins and pathogens, such as viruses, intracellular bacteria, and parasites. ABMA selectively acts within host cell late endosomes, rather than directly targeting the toxin or pathogen itself. It possesses broad-spectrum anti-infection activity [1][2].
体内研究
ABMA (2-200 mg/kg; intraperitoneal injection; female BALB/c mice) administration shields mice against nasal instillation of an LD90 of ricin [1].
体外研究
ABMA defends cells against four bacterial toxins (Corynebacterium diphtheriae (DT; EC50 of 62.9 μM), Bacillus anthracis (LT), Clostridium difficile toxin B (TcdB; EC50 of 73.3 μM), Clostridium sordellii lethal toxin (TcsL; EC50 of 86.7 μM)), three viruses (Ebola (EC50 of 3.3 μM), rabies (EC50 of 19.4 μM), dengue-4 virus (EC50 of 8.2 μM)), two species of Chlamydiales intracellular bacteria, and the parasite Leishmania infantum (EC50 of 7.1 μM) at the micromolar level [1].
In A549 cells, ABMA treatment reduces ricin cytotoxicity with an EC50 of 3.8 μM, and exhibits a protection factor (R) at 30 μM ranging from 5 to 10. ABMA maintains nearly 100% of its biological activity against ricin-induced cytotoxicity for up to six days [1].
搜索
